• Other
  • Exited

iPierian, Inc. is a biotechnology company developing novel therapies for neurodegenerative disease, specifically focused on discovering monoclonal antibodies against targets of the Tau protein. The company’s lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. iPierian was acquired by Bristol-Meyers Squibb in April 2014 for $175 million upfront, with $550 million in potential milestone payments.